Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients.

Dominique Mottier,Philippe Girard,Francis Couturaud,Karine Lacut,Emmanuelle Le Moigne,Nicolas Paleiron, Dewi Guellec,Olivier Sanchez, Virginie Cogulet,Silvy Laporte, Gisèle Marhic,Patrick Mismetti,Emilie Presles,Helia Robert-Ebadi,Isabelle Mahé,Ludovic Plaisance,Jean-Luc Reny,Pauline Darbellay Farhoumand,Clémence Cuvelier, Catherine Le Henaff, Yannick Lambert,Marc Danguy des Deserts, Claire Rousseau Legrand, Sébastien Boutreux,Yves Bleher, Romain Decours,Albert Trinh-Duc,Guillaume Armengol,Ygal Benhamou,Aurélie Daumas, Sarah-Lou Guyot, Hugo De Carvalho, Bouchra Lamia,Marc Righini,Guy Meyer,Grégoire Le Gal

NEJM evidence（2023）

引用 2|浏览10

暂无评分

摘要

Enoxaparin to Prevent Venous Thromboembolism in Older AdultsThis trial of thromboprophylaxis in medically ill, hospitalized older adults did not demonstrate that enoxaparin reduced the risk of symptomatic VTE after 1 month. Because the trial was prematurely discontinued, larger trials are needed to definitively address this question.

查看译文

关键词

symptomatic venous thromboembolism,enoxaparin,placebo,patients

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要